Prognostic impact of MGMT promoter methylation and MGMT and CD133 expression in colorectal adenocarcinoma
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Prognostic impact of MGMT promoter methylation and MGMT and CD133 expression in colorectal adenocarcinoma ; volume:14 ; number:1 ; day:11 ; month:7 ; year:2014 ; pages:1-11 ; date:12.2014
BMC cancer ; 14, Heft 1 (11.7.2014), 1-11, 12.2014
- Urheber
-
Oliver, Jaime Antonio
- Beteiligte Personen und Organisationen
-
Ortiz, Raúl
Melguizo, Consolación
Álvarez, Pablo Juan
Gómez-Millán, Jaime
Prados, Jose
SpringerLink (Online service)
- DOI
-
10.1186/1471-2407-14-511
- URN
-
urn:nbn:de:1111-2016030419612
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:34 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Oliver, Jaime Antonio
- Ortiz, Raúl
- Melguizo, Consolación
- Álvarez, Pablo Juan
- Gómez-Millán, Jaime
- Prados, Jose
- SpringerLink (Online service)
Ähnliche Objekte (12)
MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy
O6-methylguanine-DNA methyltransferase (MGMT) mRNA expression predicts outcome in malignant glioma independent of MGMT promoter methylation
MGMT, GATA6, CD81, DR4, and CASP8 gene promoter methylation in glioblastoma
MGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCR
Absence of MGMT promoter methylation in diffuse midline glioma, H3 K27M-mutant
Stem cell phenotype predicts therapeutic response in glioblastomas with MGMT promoter methylation
MGMT methylation and its prognostic significance in inoperable IDH-wildtype glioblastoma: the MGMT-GBM study
MGMT promoter methylation in triple negative breast cancer of the GeparSixto trial
MGMT promoter methylation in triple negative breast cancer of the GeparSixto trial
Recurrence in oral and pharyngeal cancer is associated with quantitative MGMT promoter methylation
Prognostic Impact of the Combination of MGMT Methylation and TERT Promoter Mutation in Glioblastoma
18F-FDG-PET-based Radiomics signature predicts MGMT promoter methylation status in primary diffuse glioma
MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy
O6-methylguanine-DNA methyltransferase (MGMT) mRNA expression predicts outcome in malignant glioma independent of MGMT promoter methylation
MGMT, GATA6, CD81, DR4, and CASP8 gene promoter methylation in glioblastoma
MGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCR
Absence of MGMT promoter methylation in diffuse midline glioma, H3 K27M-mutant
Stem cell phenotype predicts therapeutic response in glioblastomas with MGMT promoter methylation
MGMT methylation and its prognostic significance in inoperable IDH-wildtype glioblastoma: the MGMT-GBM study
MGMT promoter methylation in triple negative breast cancer of the GeparSixto trial
MGMT promoter methylation in triple negative breast cancer of the GeparSixto trial
Recurrence in oral and pharyngeal cancer is associated with quantitative MGMT promoter methylation
Prognostic Impact of the Combination of MGMT Methylation and TERT Promoter Mutation in Glioblastoma
18F-FDG-PET-based Radiomics signature predicts MGMT promoter methylation status in primary diffuse glioma
MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy
O6-methylguanine-DNA methyltransferase (MGMT) mRNA expression predicts outcome in malignant glioma independent of MGMT promoter methylation
MGMT, GATA6, CD81, DR4, and CASP8 gene promoter methylation in glioblastoma
MGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCR
Absence of MGMT promoter methylation in diffuse midline glioma, H3 K27M-mutant
Stem cell phenotype predicts therapeutic response in glioblastomas with MGMT promoter methylation
MGMT methylation and its prognostic significance in inoperable IDH-wildtype glioblastoma: the MGMT-GBM study
MGMT promoter methylation in triple negative breast cancer of the GeparSixto trial
MGMT promoter methylation in triple negative breast cancer of the GeparSixto trial
Recurrence in oral and pharyngeal cancer is associated with quantitative MGMT promoter methylation
Prognostic Impact of the Combination of MGMT Methylation and TERT Promoter Mutation in Glioblastoma